John P. Richard

Abeome Corp. operates as a biotechnology company. It develops therapeutic and diagnostic monoclonal antibodies (mAbs). The firm’s DiSH (Direct Selection of Hybridomas) technology offers a process for selecting and cloning desired hybridomas that produce antibodies with optimal binding characteristics. The company was founded by Richard B. Meagher in 2000 and is headquartered in Athens, GA.

AerovectRx Corp. provides dosage controlled solutions to the inhaled drug delivery market. It offers AeroCell disposable drug cartridge for inhaled delivery of drugs, vaccines, and therapeutics. AerovectRx technology includes treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management and for delivery of vaccines and anti-viral drugs. The company was founded in 2005 and is headquartered in Atlanta, GA.

Metastatix, Inc. develops small molecule drugs to treat life-threatening diseases including cancer, HIV infection, and macular degeneration. It has developed a series of novel oral small-molecule CXCR4 inhibitors that have unprecedented biological activity in preclinical models. The company was founded in 2005 and is located in Tucker, GA.

ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA.

Altiris Therapeutics, Inc. develops and commercializes small-molecule drug therapies. The company was founded by Dennis Liotta, Hyunsuk Shim and James P. Snyder in 2005 and is headquartered in Atlanta, GA.

J.E.M. Capital, Inc. is a a shell company, which engages in the identification of a privately held operating company which desires to become a publicly held entity by merging with the firm through a reverse merger or acquisition. The company was founded on September 14, 2011 and is headquartered in Hong Kong.

Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC.

Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA.

Aruna Bio, Inc. manufactures and provides neural stem cells. Its products include neuronet pure human neurons screening kit, neuronet pure human neurons discovery kit, co-culture kit hastropro-neuronet, hastropro human astrocytes kit and motor neurons GFP+htscreening kit. The company was founded by James Stice and Steven L. Stice in 2003 and is headquartered in Athens, GA.

Axotect, Inc. develops treatments for neurological disorders. It is a small-molecule drugs for the treatment of pain associated with Chemotherapy induced peripheral neuropathy (CPIN). The company was founded in 2005 and is headquartered in Atlanta, GA.

Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.

QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA.

Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.